Retisert (Envision TD), a sustained release intraocular implant containing fluocinolone acetonide, has been developed and launched in the US by Bausch & Lomb and Control Delivery Systems for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
|Original language||English (US)|
|Number of pages||9|
|Journal||Current Opinion in Investigational Drugs|
|State||Published - Nov 1 2005|
ASJC Scopus subject areas
- Drug Discovery